A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Exclusion Criteria

• •Participants may be excluded if they meet any of the following:
• •Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.
• •Clinically significant risk of haemorrhage or fistula
• •History of another malignancy within 3 years
• •History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• •active autoimmune diseases requiring systemic treatment within the past 2 years
• •uncontrolled cardiac and other comorbidities within 6 months prior to the first dose
• •Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study
• •History of severe bleeding tendency or coagulation dysfunction
• •History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess
• •Acute, chronic or symptomatic infections
• •Participants with history of immunodeficiency